Towards safer antibody drug conjugates

Antibody-drug conjugates (ADCs) were initially designed to increase the therapeutic index of chemotherapeutic agents and radionuclides by coupling them to antibodies with high tumor specificity. Close to 100 ADCs are in clinical development and 2 to 3 novel ADCs are likely to be approved within the next few years. Regrettably, the greatest challenge for ADCs still remains a therapeutic index narrower than anticipated. The aim of this project is to develop highly tumor specific nanobodies with increased therapeutic index.

Keywords:nanobody, VHH, ADC

Disciplines:Biopharmaceuticals, Cancer therapy